The envelope glycoprotein E2 of hepatitis C virus (HCV) is a major component of the viral envelope. Knowledge of its topologic features and antigenic determinants in virions is crucial in understanding the viral binding sites to cellular receptor(s) and the induction of neutralizing antibodies. The lack of a robust cell culture system for virus propagation has hampered the characterization of E2 presented on the virion. Here we report the structural features of hepatitis C virus-like particles (HCV-LPs) of the 1a and 1b genotypes as determined by various mouse and human monoclonal anti-envelope antibodies. Our results show that the E2 protein of HCV-LPs reacts with human monoclonal antibodies recognizing conformational determinants. Monoclonal antibodies (mAbs) specific for the hypervariable region 1 (HVR-1) sequence reacted strongly with HCV-LPs, suggesting that the HVR-1 is exposed on the viral surface. Several mAbs recognized both HCV-LPs with equally high affinity, indicating that the corresponding epitopes [amino acids (aa) 192-217 of E1 and aa 412-423, aa 522-531, and aa 640-653 of E2] are conserved in both genotypes and exposed on the surface of the HCV-LP. The E2 and E1/E2 dimers of 1a bound strongly to the recombinant large extracellular loop (LEL) of CD81 (CD81-LEL) of human and African green monkey, while the HCV-LP of 1a bound weakly to human CD81-LEL. E1/E2 dimers and the HCV-LPs of 1b did not bind CD81-LEL, consistent with the notion that CD81 recognition by E2 is strain-specific and does not correlate with permissiveness of infection. A model of the topology and exposed antigenic determinants of the envelope proteins of HCV is proposed. © 2002 Elsevier Science (USA)
INTRODUCTION
Hepatitis C virus (HCV) infection is a global health problem affecting an estimated 170 million people worldwide. The majority of HCV-infected individuals progress to chronic hepatitis despite the presence of immune responses. Attempts to elucidate the viral mechanisms of persistent infection and host factors necessary for viral clearance have been hampered by the lack of a robust cell culture system for virus propagation and convenient animal models.
HCV, a member of the Flaviviridae family, is an enveloped virus with a positive-strand RNA genome of ϳ9.6 kb. A considerable genetic heterogeneity with more than six distinct genotypes exists among different HCV isolates; however, genotypes 1a and 1b are the most prevalent worldwide (Bukh et al., 1995) . The viral genome encodes a single polyprotein of approximately ϳ3000 amino acids (aa) that is processed into the structural and nonstructural proteins by host and viral proteases, respectively. The putative structural proteins [the core and the two envelope glycoproteins (gp), E1 and E2] are located within the N-terminus of the polyprotein while the nonstructural proteins reside within the C-terminal part (for a review, see Bartenschlager and Lohmann, 2000) .
HCV E2 glycoprotein extends from aa 384 to 746 of the polyprotein and contains a region of extreme variability at the amino-terminal domain (aa 384-411), the so-called hypervariable region 1 (HVR-1). E2 protein is considered to be important for initiation of infection by binding to a cellular receptor(s) and is also known as one of the major antigenic targets of host immune responses. Sequence analyses of different HCV isolates and sequential studies of virus isolates from infected patients suggest that the HCV E2 protein under immune selection results in selection of variants within the HVR-1 (Bukh et al., 1995; Kato et al., 1990; Weiner et al., 1992) . Antibodies to HVR-1 appeared to mediate viral neutralization in vitro and in a chimpanzee protection study Farci et al., 1994) . However, antibodies to HVR-1 tend to be isolate-specific and over time drive the selection of new viral variants that are not recognized by the preexisting antibodies (Shimizu et al., 1994) .
The precise mechanism of HCV binding and entry into cells is poorly understood and CD81, a tetraspanin protein, has been proposed as a putative HCV receptor based on its interaction with a truncated form of the E2 protein (Pileri et al., 1998) . Nonetheless, there is accumulating evidence that binding between E2 and CD81 is strain or isolate specific (Yagnik et al., 2000) and does not necessarily confer susceptibility to HCV infection, at least in tamarin (a small New World monkey) and African green monkey (AGM). HCV E2 protein binds with higher affinity to tamarin CD81 than to human CD81 (Allander et al., 2000; Meola et al., 2000) and to a lesser extent to AGM CD81 (Allander et al., 2000) . At present, direct evidence that CD81 mediates HCV virion binding and entry into cells has not been established. Wünschmann et al. (2000) showed that CD81 inhibited the binding of E2 protein, but not HCV virion, to Molt-4 cells. Taken together, these results suggested either that there are conformational differences in E2 proteins between the truncated soluble form and the virion form or that HCV virions may employ another cellular receptor(s) for viral entry.
To date, as the ultrastructural features of the HCV virion remain elusive, the knowledge of antigenic determinants of HCV envelope proteins displayed on the viral particles is important for designing specific antiviral drugs and vaccines. Several groups have generated a panel of mouse and human anti-E2 monoclonal antibodies (mAbs) and mapped their epitope recognition sites within the E2 protein (Dubuisson et al., 1994; Flint et al., 1999; Habersetzer et al., 1998; Hadlock et al., 2000; Owsianka et al., 2001) . We have previously reported the generation of a recombinant baculovirus expressing HCV-like particles (HCV-LPs) containing the structural proteins of HCV derived from the J strain (1b genotype) (Baumert et al., 1998) . As part of our effort to characterize HCV-LP as a model system for the HCV virion, the goal of this study was to map the topology of envelope proteins on HCV-LPs using various anti-envelope monoclonal antibodies with well-defined epitopes. In addition, the interaction of HCV-LPs with human CD81 molecules was investigated.
RESULTS AND DISCUSSION
Recombinant baculoviruses produce HCV-LPs of 1a and 1b
Generation of HCV-LP of the 1b genotype (J strain) has been described previously (Baumert et al., 1998) . Using the same approach, recombinant baculovirus expressing HCV-LP of the 1a genotype was generated from the H77 strain of HCV (Kolykhalov et al., 1997) . Both the 1a and 1b HCV sequences used for generation of HCV-LPs were derived from clones that have been shown to be infectious in chimpanzees (Kolykhalov et al., 1997; Thomson et al., 2001) . Insect cells (Sf9) were infected with the recombinant baculovirus at m.o.i. 5 and HCV-LPs were harvested at 3 days postinfection. HCV-LPs were partially purified by equilibrium 20-60% sucrose gradient centrifugation as described (Baumert et al., 1998) . Both recombinant particles formed double-shelled particles with a predominant size of 50 nm in diameter as analyzed by electron microscopy (Baumert et al., 1998; Triyatni et al., manuscript in preparation) .
HCV-LPs assume a proper E2 conformation
Initially, we tested the antigenicity of HCV-LPs against several mouse anti-E1 and -E2 monoclonal antibodies specific for linear and conformational epitopes. As shown in Fig. 1 , HCV-LP 1a was highly reactive against two anti-E2 antibodies, H2 and H53, that recognize conformational epitopes present in E2 of the noncovalently linked E1/E2 heterodimer of the HCV 1a genotype (Deleersnyder et al., 1997; Cocquerel et al., 1998) . The recognition of HCV-LPs by these antibodies suggests that the E2 protein presented on the recombinant HCV particles adopts the proper conformation. Since a similar antibody specific for the E2 protein of the 1b genotype is not available, such an analysis for the E2 form on HCV-LP 1b is not possible.
Recognition of HCV-LPs of 1a and 1b genotypes by anti-E1 and anti-E2 monoclonal antibodies
Next, we analyzed the antigenicity of both types of HCV-LPs with a panel of anti-E1 and -E2 monoclonal antibodies. As shown in Table 1 , certain regions within the E1/E2 proteins of HCV-LP 1a and 1b were equally recognized by similar antibodies which may reflect the highly conserved regions in both genotypes (aa 192-217
Reactivities of mouse anti-E1 and -E2 mAbs to HCV-LPs. HCV-LPs of the 1a or 1b genotypes were captured on a GNA-coated ELISA plate as described under Materials and Methods. The plate was then incubated with various mouse anti-E1 or -E2 monoclonal antibodies, anti-E1 (A4) at 6 g/ml or anti-E2 (AP33 at 6 g/ml, H2 and H53 culture medium at 1/100 dilution), or mouse anti-GST IgG as a negative control. Bound antibodies were detected by peroxidase-labeled goat anti-mouse IgG. The results presented are representative of three independent experiments. of E1 and aa 412-423, aa 522-531, and aa 640-653 of E2). However, several antibodies reacted with higher affinity to HCV-LP 1a than to that of the 1b genotype because they were raised against the 1a E2 protein and some sequence heterogeneity exists within the recognized epitopes between 1a and 1b (Flint et al., 1999) . For instance, 3/11, 1/39, and AP320 antibodies (recognizing aa 412-423, aa 432-443, and aa 464-471 of E2, respectively) appeared to behave this way. As one of the major antigenic targets of the humoral response, the HVR-1 of the E2 protein (aa 384-410) should be exposed on the surface of HCV-LPs. Indeed, this was the case for HCV-LP 1a as it was recognized by two anti-HVR-1 antibodies, 7/59 and 9/27. However, these antibodies failed to recognize HVR-1 of HCV-LP 1b, most likely due to substantial sequence heterogeneity. In support of this notion, it has been shown that 3C7-C3, a broadly reactive anti-HVR 1 monoclonal antibody that can specifically capture HCV virions, also recognizes HCV-LPs of both 1a and 1b (1a more strongly than 1b) (Cerino et al., 2001 ; and our unpublished data).
As mentioned above, three regions of E2 (aa 412-423, aa 522-531, and aa 640-653) are likely exposed on the surface of HCV-LPs because the corresponding antibodies (AP33, 3E5-1, 9/75, and ALP98) reacted to both types of HCV-LPs with high affinity. Several antibodies (H, 2/69a, 7/16b, 6/1a, 6/41a, AP109, 6/53, and ALP1) failed to recognize both types of HCV-LPs. Of particular interest, 7/16b, 6/41a, and 6/53 are known to block E2-CD81 interaction (Flint et al., 1999) . These results suggest that either the corresponding epitopes are not accessible on HCV-LP or the affinities of these antibodies against the antigenic determinants are weak and therefore not detected by our assay. For example, AP33 and 3/11 antibodies recognized similar epitopes (aa 412-423) of E2, but only AP33 showed very strong affinity to both types of HCV-LPs (titer of 25,600) and 3/11 reacted only weakly (titer of 400). Likewise, a significant difference in reactivity between 3E5-1 and 9/75 antibodies that recognized overlapping epitopes between aa 522 and 531 of E2 (titer of 25,600 vs 3200) also exists. However, many of these antibodies have been shown to bind strongly to denatured and various truncated forms of E2 and E1/E2 (Flint et al., 1999) , suggesting that some of the epitopes are not exposed on the HCV-LP. Our observations are largely supported by a recent report (Wellnitz et al., 2002) on reactivities of various mouse monoclonal antibodies to HCV-LP 1a. However, they did not compare in great detail the different reactivities between the HCV-LPs of 1a and 1b.
Conformational human anti-E2 monoclonal antibodies recognize HCV-LPs
Previously, we have shown that serum samples containing anti-HCV antibodies from HCV-infected individuals (genotypes 1a, 1b, 2, 3, 4, and 5a/b) were highly reactive against HCV-LP 1b in ELISA (Baumert et al., 1999) , suggesting that epitopes presented on the envelope proteins of HCV-LP were broadly conserved among different genotypes. Hence, the recent isolation of HmAbs which recognize conserved conformational epitopes within the HCV E2 protein among different genotypes (Hadlock et al., 2000) allowed us to determine whether similar epitopes were present on HCV-LPs. Eight HmAbs, CBH-2, -4G, -5, -7, -8c, -8e, -11, and -17, exhibited reactivities with either or both recombinant particles, while no reactivity was observed with the control HmAb (R04, specific to a cytomegalovirus protein) (Fig. 2) . Although the antigenic binding sites of these HmAbs have not been mapped, they are thought to recognize conformational epitopes on the E2 protein.
The HmAbs with the highest levels of reactivity to both types of HCV-LPs were CBH-7 and CBH-8c, followed by 
Ͻ50
a Underlined sequence represents amino acids that are different from the mapped epitopes. b Titer of mAbs was determined as the serial dilution that gave OD 405 nm just below the cut-off (signal to noise ratio Ͻ2.5). c Flint et al. (1999) . ND, not determined.
CBH-5, -17, -4G, -11, -2 and -8e. The order of affinity of HmAbs shown against HCV-LPs was in general accordance with the previous study on E2 (Hadlock et al., 2000) , suggesting that the epitopes recognized by these antibodies were conserved in genotypes 1a and 1b of HCV. However, we also observed minor differences between the reactivities of HmAbs with 1a and 1b HCV-LPs and those with 1a and 1b E2 protein expressed by the vaccinia expression system (Hadlock et al., 2000) . Sequence heterogeneity and a disparate expression system may explain the differences.
HCV-LPs of 1a interact weakly with CD81
The ability of HCV-LPs to bind human CD81 was analyzed on an ELISA plate coated with the soluble GST fusion protein of the large extracellular loop (LEL) of human (wild-type or mutant T163A), AGM, or mouse CD81 (CD81-LEL). It has been shown that the T163A mutant, in comparison to the wild-type, of human CD81 showed a higher binding affinity to E2 protein (Higginbottom et al., 2000) . As a negative control, the plate was also coated with GST protein alone. CD81 binding to HCV-LPs was compared to various forms of E2 protein: mammalian-derived truncated E2 (E2 710 ) of 1a and 1b and the E1/E2 proteins of 1a (Choo et al., 1994) and 1b genotypes (Baumert et al., 1999) . While the mammalianderived E2 710 and HCV-LPs were derived from two different HCV 1a strains (PT and H77 strains, respectively), the amino acid divergence between the two strains is Ͻ5% and therefore should not contribute to any significantly different binding property. The 1b proteins were all derived from the J strain (Kato et al., 1990) . As seen in Fig.  3 , in contrast to a strong interaction with truncated E2 or E1/E2 proteins of the 1a genotype, the wild-type and
FIG. 2. Reactivities of anti-E2
HmAbs to HCV-LPs. HCV-LPs 1a and 1b were captured onto a GNA lectin-coated ELISA plate as described under Materials and Methods and then the plate was incubated with HmAbs at the indicated concentrations above. As a control, R04, a HmAb to cytomegalovirus protein, was used. Bound antibodies were detected by HRP-conjugated goat anti-human IgG. The results presented are representative of three independent experiments. T163A mutant human CD81 bound HCV-LPs 1a only at high concentrations. The large amount needed for HCVLPs might be partly because the E2 consists of only a small proportion of the total protein in the preparation. Based on Western blot analysis using various known quantities of purified truncated E2 protein as standards, we estimated that E2 consisted of ϳ1/20 of total protein in the HCV-LP preparation (data not shown). However even if we correct for the amount of E2 protein, the binding of CD81 to the HCV-LP1a is still much weaker than that to the E1/E2 proteins of genotype 1a. It is worth noting that E1/E2 of 1a also bound AGM CD81 with comparable affinity to human CD81, confirming the previous findings that the E2 protein binds CD81 proteins of AGM and tamarin in addition to that of human (Allander et al., 2000; Meola et al., 2000) . However, the T163A mutant human CD81 did bind to truncated E2 and HCV-LP 1a with higher affinity than wild-type CD81. The E1/E2 and HCV-LPs of 1b genotype did not bind to CD81. No interaction was found between mouse CD81-LEL or GST and all forms of E2 protein tested.
The weak interaction observed between HCV-LPs and CD81 is very unlikely due to the glycosylation difference of the E2 glycoprotein of HCV-LPs in insect cells. It has been demonstrated previously that the truncated E2 protein derived from both mammalian (Higginbottom et al., 2000) and insect cells (Chan-Fook et al., 2000) binds CD81, indicating that the glycan composition of the E2 protein has no direct effect on this interaction. In our hands, insect-derived E2 715 of 1a genotype also displayed a high affinity to human CD81 (data not shown).
Previously, Flint et al. (1999) proposed that CD81 binding sites on the E2 protein reside within aa 480-493 and 544-551, based on the ability of the corresponding anti-E2 monoclonal antibodies, 6/41a and 6/53, respectively, to block E2-CD81 interaction. However, our results showed that these antibodies failed to recognize both types of HCV-LPs. One plausible explanation is that the CD81 binding sites (as present on the truncated E2 protein) are less accessible on HCV-LPs. The weak interaction between HCV-LP 1a and CD81 may also explain our finding that neither CD81 nor anti-CD81 antibody was able to block HCV-LP binding to several human hepatic cell lines (Triyatni et al., manuscript in preparation). Therefore, it is possible that CD81 may not directly mediate the binding of HCV virions to suscep- FIG. 3 . Interaction of CD81 with truncated E2, E1/E2 proteins, and HCV-LPs. An ELISA plate was coated with GST fusion protein of CD81-LEL of human (wild-type and mutant T163A), AGM, or mouse as described under Materials and Methods. Truncated E2, E1/E2, or HCV-LPs from 1a and 1b genotypes were then added to each well and incubated at 4°C overnight. The plate was incubated with anti-E2 monoclonal antibody AP33 (6 g/ml), followed by peroxidase-labeled goat anti-mouse IgG. Bound antibodies were detected as described in the legend to Fig. 1 . The results presented are representative of three independent experiments. tible cells. This possibility has been raised recently (Wünschmann et al., 2000) . Hence, the CD81-E2 interaction may represent some alternative effect of the virus on cells and may play an important role in the pathogenesis of HCV infection, e.g., autoimmune manifestations (Wack et al., 2001) , and viral evasion from the immune system. CD81-E2 engagement has been shown to inhibit natural killer cell activation and interferon-␥ production (Crotta et al., 2002) , presumably as one mechanism of HCV to establish persistent infection.
Taken together, our results described in this study demonstrate that the envelope proteins of HCV-LPs display broadly conserved epitopes that are recognized by mouse and human anti-HCV antibodies. Based on the reactivities of various monoclonal antibodies tested, we proposed a model for the topology of envelope proteins on HCV-LP (Fig. 4) . Some of the exposed regions featured were in accordance with their hydrophilic characteristics as described by Yagnik et al. (2000) . Undoubtedly, additional information such as the three-dimensional structure of HCV-LP with antibody labeling would be warranted to ascertain the structure-antigenic relationship presented here. Although it remains to be seen whether the antigenic profiles of HCV-LP resemble those of the HCV virion, our data are beginning to provide a road map for the putative structure of the HCV virion.
MATERIALS AND METHODS

Anti-HCV envelope monoclonal antibodies
Anti-E1 (A4) and anti-E2 (H) antibodies were provided by H. Greenberg (Dubuisson et al., 1994) ; anti-E2 antibodies (H2 and H53) were from J. Dubuisson (Deleersnyder et al., 1997; Cocquerel et al., 1998) . 3D5/C3 and 3E5-1 (anti-E1 and anti-E2 antibodies, respectively) were from M. Houghton (personal communication). The anti-E1 antibody 159 was from J. Lau. Anti-E2 monoclonal antibodies (raised against the Glasgow strain of 1a genotype) AP33, AP320, AP109, ALP98, and ALP1 were from A. Patel (Glasgow, UK) (Owsianka et al., 2001) . Anti-E2 monoclonal antibodies (raised against H77 strain of 1a genotype) 7/59, 3/11, 2/69a, 9/27, 1/39, 6/1a, 7/16b, 6/41a, 9/75, and 6/53 were from J. McKeating (Reading, UK) (Flint et al., 1999) . Table 1 (not drawn to scale). The glycosylation sites in E1 (Meunier et al., 1999) , some of the putative glycosylation sites in E2 (Yagnik et al., 2000) , and the transmembrane domains (black boxes) at the carboxy termini of E1 (aa 353-383) and E2 (aa 718-746) (Op De Beeck et al., 2001 ) are also shown. The proposed surface-exposed regions of E1 and E2 are shown with various antibody binding sites.
E1/E2 ELISA
A 96-well ELISA plate (Immulon, Dynex Tech, VA) was coated with 100 l (20 g/ml in PBS) of GNA (lectin from Galanthus nivalis, Sigma) at 37°C for 3 h and then blocked with 150 l of 4% goat serum (in 5% skim milk-PBS) for 3 h at RT. HCV-LPs (of 1a or 1b genotype) were then added and incubated at 4°C, overnight. Various mouse anti-E1 or -E2 monoclonal antibodies were then added and the plate was incubated for 3 h at 37°C. As a negative control, mouse anti-GST IgG was used. Then 100 l of peroxidase-labeled goat anti-mouse IgG (Kirkegaard & Perry Laboratories, Gaithersburg, MD) at a dilution of 1/1000 was added and incubated for 1 h at 37°C. Bound antibodies were detected by the addition of ABTS Microwell Peroxidase Substrate System (KPL) and measured on an ELISA reader (Bio-Rad) at an optical density of 405 nm. Plates were washed six times with PBS between each step and, after the addition of the primary antibodies, with PBS-0.05% Tween 20. All dilutions were made in PBS containing 5% skim milk. To determine the reactivity of HmAb to HCV-LPs, HCV-LPs 1a or 1b were captured onto a GNA lectin-coated ELISA plate as described above. After the plate was washed, HmAbs at various concentrations were added and incubated for 3 h at 37°C. As a control, R04, a HmAb to cytomegalovirus protein, was used. Bound antibodies were detected by HRP-conjugated goat anti-human IgG.
CD81 ELISA
An ELISA plate was coated with 100 l (10 g/ml in PBS) of GST fusion protein of CD81-LEL of human (wildtype and mutant T163A), AGM, or mouse at 4°C overnight and then blocked with 150 l of 4% goat serum (in 5% skim milk-PBS) for 3 h at RT. Different sources of E2 protein (truncated E2, E1/E2, and HCV-LPs) from the 1a and 1b genotypes were added to each well and incubated at 4°C overnight. The plate was then incubated with anti-E2 monoclonal antibody AP33 (6 g/ml) for 3 h at RT, followed by peroxidase-labeled goat anti-mouse IgG at a dilution of 1/1000 for 1 h at RT. Bound antibodies were detected as for the E1/E2 ELISA.
